Questionnaires to Identify Chinese Patients at Risk for Obstructive Sleep Apnea
Obstructive Sleep Apnea
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Validation of Questionnaires to Identify Chinese Patients at Risk for Obstructive Sleep Apnea|
- To validate the Berlin questionnaire and STOP-BANG as effective screening tools [ Time Frame: at the time of completing the questionnaire ]To validate the Berlin questionnaire and STOP-BANG as effective screening tools for Chinese subjects who are suspected to have OSA
- the predictive performance on OSA of Berlin questionnaire and STOP-BANG [ Time Frame: at the time of completing questionnaire ]To compare the predictive performance on OSA of Berlin questionnaire and STOP-BANG in our Chinese population
|Study Start Date:||July 2010|
|Study Completion Date:||August 2014|
|Primary Completion Date:||April 2014 (Final data collection date for primary outcome measure)|
Obstructive sleep apnea (OSA) is a common sleep related breathing disorder associated with excessive daytime sleepiness and cardiovascular disease. It is prevalent in both western (4-26%) and eastern countries (4-19%). In recent studies, it has been estimated that at least 70-80% of middle aged individuals with sleep apnea are undiagnosed and untreated. The prevalence of undiagnosed OSA subjects within the community suggests the need for a greater awareness and a high index of suspicion of this disease entity as well as its associated short- and long-term comorbidities.
A reliable and easy-to-use screening questionnaire is required for efficient prediction of OSA and treatment arrangement. It would be helpful to prioritize patients who require sleep study according to the probability of suffering from sleep apnea. It reduces the use of sleep study for those with low probability of having OSA, but giving treatment to those who are with more severe OSA first. Meanwhile, it enhances the cost effective management of disease especially with limited resources in our society.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01171196
|Queen Mary Hospital|
|Hong Kong Island, Hong Kong|
|Principal Investigator:||Agnes YK Lai, MSc||The University of Hong Kong|